9 years ago

Inotec AMD Secures Venture Capital Funding for Expansion and Clinical Trials

  • Inotec AMD, a Cambridge, UK-based medical device company specializing in treating chronic wounds, has received venture capital funding from Amadeus Capital Partners

  • The investment will be used for large-scale clinical trials, expanding product applications, establishing international partnerships, and expanding globally

  • Inotec's NATROX™ system, which delivers continuous humidified oxygen to wounds, has demonstrated significant wound reduction in preliminary trials and is CE marked and FDA approved.

      • ProblemHealthcare

      "Chronic, hypoxic wounds are a major healthcare burden, often requiring long and expensive treatments."

      Solution

      "Inotec AMD's NATROX™ system is a compact, wearable device that delivers a continuous supply of pure, humidified oxygen to wounds, accelerating healing."

      Covered on